Skip to main content
Nykode Therapeutics ASA logo

Nykode Therapeutics ASA — Investor Relations & Filings

Ticker · NYKD ISIN · NO0010714785 LEI · 254900UKQHWYZJD22017 OL Manufacturing
Open in API
Filings indexed 493 across all filing types
Latest filing 2023-05-12 Report Publication Anno…
Country NO Norway
Listing OL NYKD

About Nykode Therapeutics ASA

https://nykode.com/

Nykode Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immunotherapies. The company's core is its proprietary Vaccibody™ technology, a modular platform designed to create targeted vaccines. This technology works by linking antigens to a targeting unit, which delivers them directly to antigen-presenting cells. This mechanism is engineered to induce rapid, potent, and long-lasting T-cell and antibody immune responses. Nykode's development pipeline is focused on generating therapeutics for a range of diseases, with a primary emphasis on oncology and infectious diseases.

Recent filings

Filing Released Lang Actions
Nykode Therapeutics - Quarterly report Q1 2023
Report Publication Announcement Classification · 100% confidence The document is a short announcement (approx. 2,700 characters) that notifies the public of the release of the Q1 2023 financial results. It does not contain the actual financial statements or substantive financial data, but rather provides a link to the company's website where the report can be accessed. Per the 'Menu vs Meal' rule, this is classified as a Report Publication Announcement (RPA). Q1 2023
2023-05-12 English
Nykode Therapeutics ASA - Minutes of Annual General Meeting
AGM Information Classification · 100% confidence The document is explicitly titled 'PROTOKOLL FRA ORDINÆR GENERALFORSAMLING I NYKODE THERAPEUTICS ASA' and 'MINUTES OF THE ANNUAL GENERAL MEETING IN NYKODE THERAPEUTICS ASA'. It details the proceedings, resolutions passed (including approval of annual accounts, remuneration guidelines, board elections, and authorization to issue shares), and the date of the meeting (May 11, 2023). This content perfectly matches the definition of minutes from an Annual General Meeting. Although it discusses the approval of the Annual Report (Item 3), the document itself is the record of the meeting, not the report itself. Therefore, the correct classification is AGM-R.
2023-05-11 English
Nykode Therapeutics ASA - Minutes of Annual General Meeting
AGM Information Classification · 98% confidence The document is explicitly titled "Nykode Therapeutics ASA - Minutes of Annual General Meeting" and confirms that the Annual General Meeting (AGM) was held on May 11, 2023, with all resolutions approved. The content describes the outcome of the AGM and mentions that the 'Minutes of the meeting are attached hereto.' While it contains company background information, the primary subject is the AGM proceedings and results. This aligns directly with the definition for AGM Information (AGM-R). It is not a DVA (Declaration of Voting Results) because it is the minutes/record of the meeting, not just the formal announcement of the results, and it is not a PSI (Proxy Solicitation) as it is post-meeting documentation.
2023-05-11 English
Disclosure of voting rights at AGM
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document explicitly discusses the 'Disclosure of voting rights at AGM' and details the number of shares represented by proxies held by the Chair of the Board for the upcoming Annual General Meeting (AGM). This content directly relates to the voting structure and rights associated with the meeting, which aligns perfectly with the definition of 'Declaration of Voting Results & Voting Rights Announcements' (DVA), even though the results themselves might be preliminary or related to proxy holdings before the final vote count. It is not the AGM presentation (AGM-R), nor is it a general proxy solicitation (PSI); it is a specific disclosure about voting power.
2023-05-10 English
Financial calendar
Report Publication Announcement Classification · 99% confidence The document is titled 'Financial calendar' and lists scheduled dates for future corporate events, specifically mentioning 'Half-yearly Report', 'Annual General Meeting', and 'Quarterly Report'. It does not contain the content of any of these reports, nor is it an announcement of a specific report release (like an ER or RPA). It is a forward-looking schedule of key financial and corporate events. This type of forward-looking schedule or calendar does not fit neatly into the provided specific categories (like 10-K, ER, AGM-R, etc.). Therefore, the most appropriate fallback category is Regulatory Filings (RNS), as it is a general corporate disclosure.
2023-05-08 English
Nykode Therapeutics to announce financial results for the first quarter 2023 and host webcast presentation on May 12, 2023
Report Publication Announcement Classification · 99% confidence The document is a short announcement stating that Nykode Therapeutics will report its financial results for the first quarter of 2023 on a specific future date (May 12, 2023) and will host a webcast presentation. It does not contain the actual financial results or the full report itself. According to Rule #2 (The 'MENU VS MEAL' Rule), a short announcement regarding the publication or timing of a report points towards a Report Publication Announcement (RPA). The text explicitly announces the upcoming release of financial results and the associated presentation.
2023-05-08 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.